title: [ABO-incompatible kidney transplantion].
abstract: The widespread worldwide implementation of ABO-incompatible kidney transplantation (ABOi KT) programs have increased the chances of gaining access to kidney transplantation. In Italy the practice of ABOi KT has somewhat lagged behind that practiced in many other European Countries. Even though some Italian Transplant Centers have recently started ABOi KT programs, most of them appear still reluctant in adopting this procedure. In this paper, nephrologists from two different Italian Transplant Centers express their contrasting point of view concerning specific issues related to ABOi KT. The first issue concerns the safety and efficacy of ABOi KT and how it compares with HLA-incompatible kidney transplantation. The second concerns to what extent does ABOi KT be adopted, whenever a paired kidney exchange program is available. The third issue regards the indications or contraindications of ABOi KT in specific patient categories. The last issue is about the economical sustainability of ABOi KT programs nowadays. The different point of views of the discussants are summarized in the context of the most recent available evidence.
authors.forename: Umberto
authors.initials: U
authors.lastname: Maggiore
authors.forename: Giovanni M
authors.initials: GM
authors.lastname: Frascà
authors.forename: Maria Stefania
authors.initials: MS
authors.lastname: Pugliese
authors.forename: Giuliana
authors.initials: G
authors.lastname: Tognarelli
mesh_terms: D001739:BK Virus; D001787:Blood Group Incompatibility / Q000276:immunology*; D000075202:Contraindications; D006084:Graft Rejection; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology; D006801:Humans; D007518:Isoantibodies / Q000096:biosynthesis; D007558:Italy; D016030:Kidney Transplantation / Q000009:adverse effects / Q000191:economics / Q000592:standards; D027601:Polyomavirus Infections / Q000209:etiology / Q000276:immunology; D011183:Postoperative Complications / Q000453:epidemiology / Q000276:immunology; D012306:Risk; D014019:Tissue Donors / Q000600:supply & distribution; D009927:Tissue and Organ Procurement / Q000458:organization & administration / Q000592:standards; D016896:Treatment Outcome; D014412:Tumor Virus Infections / Q000209:etiology / Q000276:immunology
chemical_list: D007518:Isoantibodies